29 Sep 2024
// PRRESS RELEASE
22 Jan 2024
// FDA
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=208555
13 Dec 2023
// FDA
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-december-13-2023-38736.pdf
07 Jun 2023
// FDA
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-june-7-2023-80553.pdf
05 Jun 2023
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/cali-biosciences-initiates-second-phase-iii-study-of-cpl-01-long-acting-ropivacaine-to-decrease-post-operative-pain-and-reduce-or-eliminate-opioid-use-and-presents-consistent-and-predictable-pk-results-across-multiple-surgeries-301841948.html
18 Apr 2023
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/cali-biosciences-initiates-phase-iii-studies-of-cpl-01-long-acting-ropivacaine-to-decrease-post-operative-pain-and-reduce-or-eliminate-opioid-use-301801255.html